SAN DIEGO--(BUSINESS WIRE)--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) today announced that it has scheduled the following investor conference presentations and third quarter 2008 conference call to review its clinical development programs and provide an update on operating results:
